바다이야기 넥슨 31.ryp383.top 정글북

릴황 금성 38.ryp383.top 바로가기 바다이야기릴게임, 황금성게임공략방법

야마토사이트오징어 릴게임바다이야기 먹튀 돈 받기바다이야기 황금고래

인터넷백경 33.ryp383.top 오션파라다이스7

오션슬롯주소 82.ryp383.top 야마토2게임주소

황금성게임어플 95.ryp383.top 온라인빠찡고

오션파라다이스 예시 31.ryp383.top 모바일게임

스위피릴게임 62.ryp383.top 릴게임갓

바다이야기노무현 79.ryp383.top 강원랜드슬롯머신

슬롯 머신 제작 53.ryp383.top 신천지 게임

다빈치릴게임먹튀 54.ryp383.top 황금성오락실게임

빠친코게임 56.ryp383.top 야마토5게임기

오션바다이야기게임 94.ryp383.top 황금성포커성

릴게임다운 인터넷바다이야기 강원랜드이기는법 상품권릴게임 골드몽 백경 바나나게임 pc야마토게임 릴게임손오공 상품권릴게임 온라인신천지 알라딘게임잭팟 해저이야기사이트 바다이야기먹튀 놀이터 릴박스 100원바다이야기 메이저 슬롯사이트 릴게임5만릴게임사이다 황금성 신 천지 게임 알라딘바로가기 부산야마토 신 바다이야기 슬롯머신게임 알라딘온라인릴게임 바다이야기 꽁머니 환전 윈윈 무료슬롯머신777 온라인바다이야기 바다이야기 먹튀 신천지릴게임 바다이야기 넥슨 슬롯머신무료 황금성 게임 사설바둑이 오션파라다이스예시 모바일 야마토 릴게임신천지사이트 야마토 일본빠칭코게임 온라인릴게임사이트 오션파라다이스 무료충전게임 체리마스터 릴게임 슬롯 게시판 슬롯게임 순위 황금성잭팟 유니티 슬롯 머신 황금성게임랜드 황금성게임공략법 야마토5게임방법 인터넷바다이야기 메타슬롯 바다이야기 먹튀 신고 종합 릴게임 최신 인터넷게임 바다이야기동영상 오션파라다이스 먹튀 황금성갈가리 신규 릴게임 카카오 야마토 먹튀 야마토게임다운 알라딘 릴게임 배터리게임 야먀토5 빠찡코 알라딘온라인릴게임 바다이야기 도박 놀이터 릴박스 오리 지날 바다 체리마스터 확률 일본경륜 신천지게임 다운로드 바다이야기노무현 무료슬롯머신 온라인릴게임먹튀검증 릴게임정글북 릴게임5만릴게임사이다 무료 슬롯 메타 바다이야기 게임 인터넷야마토주소 릴게임정글북 온라인 슬롯 배팅법 바다이야기먹튀돈받기 온라인야마토 바다이야기 먹튀사이트 바다이야기2화 알라딘꽁머니 야마토다운로드 슬롯릴게임 체리마스터 다운 릴게임보물섬 신바다이야기 바다신2 다운로드 백경게임예시 야마토 동영상 야마토2 릴게임 골드몽 먹튀 슬롯머신 게임 바다이야기 pc용 무료게임 릴게임꽁머니 바다이야기꽁머니 릴게임 정보 릴게임강시 바다이야기pc게임 일본빠칭코게임 파친코게임다운로드 바다이야기2화 황금성검증 야마토3다운로드게임사이트 온라인백경 신천지게임다운로드 바다이야기 꽁머니 슬롯추천 야마토3게임 10원야마토 바다이야기넥슨 바다이야기오리지널 야마토하는법 야마토온라인주소 모바일 바다이야기 인터넷백경 릴게임연타 바다이야기무료머니 슬롯게임 실시간 This article was released as Pharm Edaily Premium Content on September 21, 2025, at 2:18 PM.


[Shin-Min Joon, Edaily Reporter] On the 19th shares of Korean biopharmaceutical companies Olix and Hanmi Pharmaceutical both developing new drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) posted notable gains.
The surge was driven by optimism sur 카드 할부 이자 계산기 rounding the MASH market after global pharma giant Roche announced plans to acquire a MASH drug developer for approximately 5 trillion won. Additionally Ildong Pharmaceutical’s stock rose after a prev sbi저축은행 모델 iously paywalled article from Pharmedaily regarding its obesity drug trial was made publicly available.



Olix stock trend on Sep 19. (Image=MP Doctor)
우리은행저소득전세자금대출


Roche to Acquire MASH Drug Developer for 5 Trillion Won

According to KG Zeroin’s MP DOCTOR (formerly Market Point), shares of Olix rose 1 핸드폰 남은 할부금 8.46% on the day to 100,100 won. The surge followed news that Roche will acquire 89Bio, a U.S.-based MASH drug developer, for up to $3.5 billion (approximately 5 trillion won), with the deal expected 재테크 카페 to close in Q4 of this year. After the acquisition, 89Bio will be integrated into Roche’s pharmaceutical division.
89Bio is currently conducting Phase 3 trials for its MASH drug candidate, pegozafermin. MASH is a chronic liver disease associated with obesity and metabolic disorders, potentially progressing to fibrosis, cirrhosis, and liver-related mortality. In 2023, 89Bio’s Phase 2b trial showed promising results in fibrosis improvement. The company is expected to release Phase 3 results in the first half of 2027.
Olix previously licensed its own MASH and obesity treatment candidate, OLX702A, to Eli Lilly in February for $630 million (approx. 911.7 billion won at the time). OLX702A is based on promising genetic targets identified through genome-wide association studies (GWAS), a method for finding disease-related genes by analyzing genomic variations in large populations.
Preclinical studies demonstrated that OLX702A not only showed efficacy in MASH and liver fibrosis, but also in other cardiovascular and metabolic diseases. Currently, a Phase 1 trial is ongoing in Australia, with the Clinical Study Report (CSR) expected in the first half of next year.
In addition to its MASH drug, Olix is also developing OLX301A for wet age-related macular degeneration and OLX104C for male-pattern hair loss. OLX301A is undergoing Phase 1 trials, with a CSR expected within the year. OLX104C completed its Phase 1a trial in January.
An Olix representative stated, “Roche’s acquisition of 89Bio has increased expectations for the MASH treatment market.”
Hanmi Pharmaceutical’s Triple Agonist Draws Attention
Shares of Hanmi Pharmaceutical also jumped 8.42% to 360,500 won. The rally appears to be driven by investor optimism over the company’s MASH drug pipeline. Hanmi currently has two MASH drug candidates under development. One of them, efocipegtrutide, is in Phase 2b trials in both Korea and the United States.
Efocipegtrutide is a long-acting triple agonist that targets glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1), enhanced through Hanmi’s LAPSCOVERY platform. It has received Fast Track designation from the U.S. Food and Drug Administration (FDA) based on promising results in preclinical and early-phase trials.
Hanmi also out licensed epinopegdutide to Merck (MSD) in 2020, which is now in Phase 2 trials. Results are expected by year end. Epinopegdutide is a long acting dual agonist targeting GLP-1 and glucagon receptors.
With obesity and diabetes on the rise, the global MASH drug market is expected to expand. Market research firm DataM Intelligence forecasts that the MASH treatment market will grow from $7.8 billion (approx. 11 trillion won) in 2024 to $31.8 billion (approx. 44 trillion won) by 2033.
A Hanmi spokesperson said, “Hanmi is exploring innovative drug development across various therapeutic areas, not limited to specific diseases, and expanding its pipeline accordingly.”
Ildong’s Oral Obesity Drug Raises Hopes
Ildong Pharmaceutical shares rose 7.90% to 30,050 won, driven by anticipation over the upcoming topline results of its Phase 1 trial for the oral obesity drug ID110521156. Among Korean companies Ildong is leading in the clinical development of oral obesity drugs. Interim results have already shown competitive weight loss efficacy compared to global players.
A Pharmedaily article released on the day stated that the key lies in high dose data though even low doses have already proven effective. The article suggested that global benchmark results may be attainable.
ID110521156 achieved an average weight loss of 6.9% after four weeks in its Phase 1 interim results. The drug outperformed rivals such as Roche and Viking Therapeutics across both low and high dose groups.
Unlike injectable GLP-1 peptide drugs like Wegovy or Mounjaro ID110521156 is a small molecule GLP-1 agonist enabling better gastrointestinal absorption and higher success potential as an oral formulation.
The drug also showed only mild gastrointestinal side effects. In comparison Viking Therapeutics had a treatment discontinuation rate of 20% due to adverse effects. Ildong is expected to present topline data from the trial during a company presentation (NDR) for institutional investors on the 29th.
Ildong stated in a recent disclosure “We will hold an investor presentation on the 29th for institutional investors and analysts to enhance understanding and boost corporate value” adding “Topline results from the Phase 1 trial of ID110521156 will be revealed during the session.”
신민준 (adonis@edaily.co.kr